NCT01421563View on ClinicalTrials.gov

Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Healthy
Interventions
DRUG

Anplag

Sarpogrelate HCl 300mg once a day or 100mg three times a day

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY